{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:02:54Z","timestamp":1776405774750,"version":"3.51.2"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Cabozantinib is an oral multi-tyrosine kinase inhibitor (TKI) that has been approved in Europe for advanced renal cell carcinoma, hepatocellular carcinoma, locally advanced and metastatic medullary thyroid carcinoma (MTC) and radioiodine-refractory differentiated thyroid cancer. Merkel cell carcinoma (MCC) is a rare and highly aggressive cutaneous malignant neuroendocrine tumour that usually presents in sun-exposed skin areas of immunosuppressed patients. Conflicting data exist about cabozantinib for MCC and this TKI is currently under investigation in several onco-endocrine frameworks.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We herein report a case of an 83-year-old man who was diagnosed with MCC during the treatment of an advanced metastatic MTC. The diagnosis of MCC was established based on clinical, histopathologic evaluation and immunohistochemistry. A systematic review of the literature on cabozantinib use for advanced endocrine and neuroendocrine tumours has been performed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The patient was initially treated with surgery and adjuvant radiotherapy. Cabozantinib was therefore started to control both MTC and MCC. After 24 months, no sign of local or metastatic MCC relapse was evidenced.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Promising data on cabozantinib treatment for endocrine and neuroendocrine neoplasms is recently emerging in the literature. In our clinical case, we reported that, besides the good response for the MTC, cabozantinib also seems to effectively control metastatic MCC, along with efficient surgery and adjuvant radiotherapy. Further investigations are needed to determine the efficacy and safety of cabozantinib in MCC patients and in off-label endocrine tumours.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12020-023-03526-0","type":"journal-article","created":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T12:02:19Z","timestamp":1697630539000},"page":"26-40","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Cabozantinib for different endocrine tumours: killing two birds with one stone. A systematic review of the literature"],"prefix":"10.1007","volume":"83","author":[{"given":"Elena","family":"Zago","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Galluzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Pradella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Petrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clotilde","family":"Sparano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,18]]},"reference":[{"key":"3526_CR1","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","volume":"10","author":"FM Yakes","year":"2011","unstructured":"F.M. Yakes, J. Chen, J. Tan, K. Yamaguchi, Y. Shi, P. Yu, F. Qian, F. Chu, F. Bentzien, B. Cancilla, J. Orf, A. You, A.D. Laird, S. Engst, L. Lee, J. Lesch, Y.-C. Chou, A.H. Joly, Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth. Mol. Cancer Ther. 10, 2298\u20132308 (2011). https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0264","journal-title":"Mol. Cancer Ther."},{"key":"3526_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2174\/1574892810666150708110816","volume":"10","author":"P Fallahi","year":"2015","unstructured":"P. Fallahi, S. Ferrari, F. Bari, G. Materazzi, S. Benvenga, P. Miccoli, A. Antonelli, Cabozantinib in Thyroid Cancer. Recent Pat. Anticancer Drug Discov. 10, 259\u2013269 (2015). https:\/\/doi.org\/10.2174\/1574892810666150708110816","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"3526_CR3","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","volume":"22","author":"MS Brose","year":"2021","unstructured":"M.S. Brose, B. Robinson, S.I. Sherman, J. Krajewska, C.-C. Lin, F. Vaisman, A.O. Hoff, E. Hitre, D.W. Bowles, J. Hernando, L. Faoro, K. Banerjee, J.W. Oliver, B. Keam, J. Capdevila, Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 22, 1126\u20131138 (2021). https:\/\/doi.org\/10.1016\/S1470-2045(21)00332-6","journal-title":"Lancet Oncol."},{"key":"3526_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6947-7-16","volume":"7","author":"C Schardt","year":"2007","unstructured":"C. Schardt, M.B. Adams, T. Owens, S. Keitz, P. Fontelo, Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med. Inform. Decis. Mak. 7, 16 (2007). https:\/\/doi.org\/10.1186\/1472-6947-7-16","journal-title":"BMC Med. Inform. Decis. Mak."},{"key":"3526_CR5","doi-asserted-by":"publisher","first-page":"b2700","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"A. Liberati, D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gotzsche, J.P.A. Ioannidis, M. Clarke, P.J. Devereaux, J. Kleijnen, D. Moher, The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339, b2700\u2013b2700 (2009). https:\/\/doi.org\/10.1136\/bmj.b2700","journal-title":"BMJ"},{"key":"3526_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","volume":"67","author":"MB Amin","year":"2017","unstructured":"M.B. Amin, F.L. Greene, S.B. Edge, C.C. Compton, J.E. Gershenwald, R.K. Brookland, L. Meyer, D.M. Gress, D.R. Byrd, D.P. Winchester, The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a popula-based to a more \u201cpersonalized\u201d approach to cancer staging: The Eighth Edition AJCC Cancer Staging Manual, CA. Cancer J. Clin. 67, 93\u201399 (2017). https:\/\/doi.org\/10.3322\/caac.21388","journal-title":"Cancer J. Clin."},{"key":"3526_CR7","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s40618-014-0062-0","volume":"37","author":"F Nardi","year":"2014","unstructured":"F. Nardi, F. Basolo, A. Crescenzi, et al., Italian consensus for the classification and reporting of thyroid cytology. J. Endocrinol. Investig. 37, 593\u2013599 (2014)","journal-title":"J. Endocrinol. Investig."},{"key":"3526_CR8","unstructured":"M. Tuttle, L.F. Morris, B. Haugen, J. Shah, J.A. Sosa, E. Rohren, R.M. Subramaniam, J.L. Hunt, N.D. Perrier, M.B. Amin, S.B. Edge, F. Greene, D. Byrd, R.K. Brookland, M.K. Washington, C.C. Compton, K.R. Hess, D.C. Sullivan, J.M. Jessup, Thyroid-differentiated and anaplastic carcinoma (Chapter 73), Springer International Publishing, n.dA."},{"key":"3526_CR9","doi-asserted-by":"publisher","first-page":"1120799","DOI":"10.3389\/fonc.2023.1120799","volume":"13","author":"C Sparano","year":"2023","unstructured":"C. Sparano, V. Adornato, M. Puccioni, E. Zago, G. Perigli, B. Badii, R. Santoro, M. Maggi, L. Petrone, Early calcitonin levels in medullary thyroid carcinoma: Prognostic role in patients without distant metastases at diagnosis. Front. Oncol. 13, 1120799 (2023). https:\/\/doi.org\/10.3389\/fonc.2023.1120799","journal-title":"Front. Oncol."},{"key":"3526_CR10","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), (2017)"},{"key":"3526_CR11","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejca.2022.03.043","volume":"171","author":"M-L Gauci","year":"2022","unstructured":"M.-L. Gauci, C. Aristei, J.C. Becker, A. Blom, V. Bataille, B. Dreno, V. Del Marmol, A.M. Forsea, M.C. Fargnoli, J.-J. Grob, F. Gomes, A. Hauschild, C. Hoeller, C. Harwood, N. Kelleners-Smeets, R. Kaufmann, A. Lallas, J. Malvehy, D. Moreno-Ramirez, K. Peris, G. Pellacani, P. Saiag, A.J. Stratigos, R. Vieira, I. Zalaudek, A.C.J. Van Akkooi, P. Lorigan, C. Garbe, C. Lebb\u00e9, Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline \u2013 Update 2022. Eur. J. Cancer 171, 203\u2013231 (2022). https:\/\/doi.org\/10.1016\/j.ejca.2022.03.043","journal-title":"Eur. J. Cancer"},{"key":"3526_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009). https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur. J. Cancer"},{"key":"3526_CR13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","volume":"25","author":"SA Wells","year":"2015","unstructured":"S.A. Wells, S.L. Asa, H. Dralle, R. Elisei, D.B. Evans, R.F. Gagel, N. Lee, A. Machens, J.F. Moley, F. Pacini, F. Raue, K. Frank-Raue, B. Robinson, M.S. Rosenthal, M. Santoro, M. Schlumberger, M. Shah, S.G. Waguespack, Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma: The American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma. Thyroid 25, 567\u2013610 (2015). https:\/\/doi.org\/10.1089\/thy.2014.0335","journal-title":"Thyroid"},{"key":"3526_CR14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1586\/14737140.8.4.625","volume":"8","author":"MB Lodish","year":"2008","unstructured":"M.B. Lodish, C.A. Stratakis, RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer. Expert Rev. Anticancer Ther. 8, 625\u2013632 (2008). https:\/\/doi.org\/10.1586\/14737140.8.4.625","journal-title":"Expert Rev. Anticancer Ther."},{"key":"3526_CR15","doi-asserted-by":"publisher","unstructured":"L. Fugazzola, Medullary thyroid cancer - An update, Best Pract. Res. Clin. Endocrinol. Metab. 37 (2023). https:\/\/doi.org\/10.1016\/j.beem.2022.101655.","DOI":"10.1016\/j.beem.2022.101655"},{"key":"3526_CR16","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.5858\/2006-130-1014-IOMPAC","volume":"130","author":"RM Ruggeri","year":"2006","unstructured":"R.M. Ruggeri, S. Sciacchitano, E. Vitarelli, F. Trimarchi, G. Barresi, M. Trovato, Immunoexpression of Multidrug-Resistance Protein 2 and Cyclooxygenase 2 in Medullary Thyroid Carcinomas. Arch. Pathol. Lab. Med. 130, 1014\u20131019 (2006). https:\/\/doi.org\/10.5858\/2006-130-1014-IOMPAC","journal-title":"Arch. Pathol. Lab. Med."},{"key":"3526_CR17","doi-asserted-by":"publisher","unstructured":"A. Hegde, A.Y. Andreev-Drakhlin, J. Roszik, L. Huang, S. Liu, K. Hess, M. Cabanillas, M.I. Hu, N.L. Busaidy, S.I. Sherman, R. Dadu, E.G. Grubbs, S.M. Ali, J. Lee, Y.Y. Elamin, G.R. Simon, G.R. Blumenschein, V.A. Papadimitrakopoulou, D. Hong, F. Meric-Bernstam, J. Heymach, V. Subbiah, Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies, ESMO Open. 5 (2020). https:\/\/doi.org\/10.1136\/esmoopen-2020-000799.","DOI":"10.1136\/esmoopen-2020-000799"},{"key":"3526_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-021-08257-x","volume":"21","author":"Z Maghsoomi","year":"2021","unstructured":"Z. Maghsoomi, Z. Emami, R. Malboosbaf, M. Malek, M.E. Khamseh, Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review. BMC Cancer 21, 579 (2021). https:\/\/doi.org\/10.1186\/s12885-021-08257-x","journal-title":"BMC Cancer"},{"key":"3526_CR19","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1089\/thy.2013.0137","volume":"23","author":"F Bentzien","year":"2013","unstructured":"F. Bentzien, M. Zuzow, N. Heald, A. Gibson, Y. Shi, L. Goon, P. Yu, S. Engst, W. Zhang, D. Huang, L. Zhao, V. Vysotskaia, F. Chu, R. Bautista, B. Cancilla, P. Lamb, A.H. Joly, F.M. Yakes, In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Thyroid 23, 1569\u20131577 (2013). https:\/\/doi.org\/10.1089\/thy.2013.0137","journal-title":"Thyroid"},{"key":"3526_CR20","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1200\/JCO.2010.32.4145","volume":"29","author":"R Kurzrock","year":"2011","unstructured":"R. Kurzrock, S.I. Sherman, D.W. Ball, A.A. Forastiere, R.B. Cohen, R. Mehra, D.G. Pfister, E.E.W. Cohen, L. Janisch, F. Nauling, D.S. Hong, C.S. Ng, L. Ye, R.F. Gagel, J. Frye, T. M\u00fcller, M.J. Ratain, R. Salgia, Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer. J. Clin. Oncol. 29, 2660\u20132666 (2011). https:\/\/doi.org\/10.1200\/JCO.2010.32.4145","journal-title":"J. Clin. Oncol."},{"key":"3526_CR21","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1093\/annonc\/mdx479","volume":"28","author":"M Schlumberger","year":"2017","unstructured":"M. Schlumberger, R. Elisei, S. M\u00fcller, P. Sch\u00f6ffski, M. Brose, M. Shah, L. Licitra, J. Krajewska, M.C. Kreissl, B. Niederle, E.E.W. Cohen, L. Wirth, H. Ali, D.O. Clary, Y. Yaron, M. Mangeshkar, D. Ball, B. Nelkin, S. Sherman, Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann. Oncol. 28, 2813\u20132819 (2017). https:\/\/doi.org\/10.1093\/annonc\/mdx479","journal-title":"Ann. Oncol."},{"key":"3526_CR22","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","volume":"31","author":"R Elisei","year":"2013","unstructured":"R. Elisei, M.J. Schlumberger, S.P. M\u00fcller, P. Sch\u00f6ffski, M.S. Brose, M.H. Shah, L. Licitra, B. Jarzab, V. Medvedev, M.C. Kreissl, B. Niederle, E.E.W. Cohen, L.J. Wirth, H. Ali, C. Hessel, Y. Yaron, D. Ball, B. Nelkin, S.I. Sherman, Cabozantinib in Progressive Medullary Thyroid Cancer. J. Clin. Oncol. 31, 3639\u20133646 (2013). https:\/\/doi.org\/10.1200\/JCO.2012.48.4659","journal-title":"J. Clin. Oncol."},{"key":"3526_CR23","doi-asserted-by":"publisher","first-page":"3856","DOI":"10.1002\/cncr.30252","volume":"122","author":"SI Sherman","year":"2016","unstructured":"S.I. Sherman, D.O. Clary, R. Elisei, M.J. Schlumberger, E.E.W. Cohen, P. Sch\u00f6ffski, L.J. Wirth, M. Mangeshkar, D.T. Aftab, M.S. Brose, Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Cancer 122, 3856\u20133864 (2016). https:\/\/doi.org\/10.1002\/cncr.30252","journal-title":"Cancer"},{"key":"3526_CR24","doi-asserted-by":"publisher","first-page":"A616","DOI":"10.1016\/j.jval.2014.08.2173","volume":"17","author":"C Rinciog","year":"2014","unstructured":"C. Rinciog, K.J. Myr\u00e9n, M. Ald\u00e9n, A. Diamantopoulos, C. Le Reun, An indirect treatment comparison of cabozantinib verse vandetan ib in progressive medullary thyroid cancer (MTC). Value Health 17, A616\u2013A617 (2014). https:\/\/doi.org\/10.1016\/j.jval.2014.08.2173","journal-title":"Value Health"},{"key":"3526_CR25","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1089\/thy.2022.0027","volume":"32","author":"J Capdevila","year":"2022","unstructured":"J. Capdevila, A. Klochikhin, S. Leboulleux, P. Isaev, C. Badiu, B. Robinson, B.G.M. Hughes, B. Keam, F. Parnis, R. Elisei, P. Gajate, H.K. Gan, E. Kapiteijn, L. Locati, M. Mangeshkar, L. Faoro, J. Krajewska, B. Jarzab, A Randomized, Double-Blind Noninferiority Study to Evaluate the Efficacy of the Cabozantinib Tablet at 60 mg per Day Compared with the Cabozantinib Capsule at 140 mg per Day in Patients with Progressive, Metastatic Medullary Thyroid Cancer. Thyroid 32, 515\u2013524 (2022). https:\/\/doi.org\/10.1089\/thy.2022.0027","journal-title":"Thyroid"},{"key":"3526_CR26","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1089\/thy.2020.0206","volume":"31","author":"VF Koehler","year":"2021","unstructured":"V.F. Koehler, P. Adam, K. Frank-Raue, F. Raue, E. Berg, E. Hoster, S. Allelein, M. Schott, M. Kroiss, C. Spitzweg; on Behalf of the German Study Group for Rare Malignant Tumors of the Thyroid and Parathyroid Glands, Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer. Thyroid 31, 459\u2013469 (2021). https:\/\/doi.org\/10.1089\/thy.2020.0206","journal-title":"Thyroid"},{"key":"3526_CR27","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.3390\/cancers14153800","volume":"14","author":"C Sparano","year":"2022","unstructured":"C. Sparano, S. Moog, J. Hadoux, C. Dupuy, A. Al Ghuzlan, I. Breuskin, J. Guerlain, D. Hartl, E. Baudin, L. Lamartina, Strategies for Radioiodine Treatment: What\u2019s New. Cancers 14, 3800 (2022). https:\/\/doi.org\/10.3390\/cancers14153800","journal-title":"Cancers"},{"key":"3526_CR28","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"H. Sung, J. Ferlay, R.L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal, F. Bray, Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, CA. Cancer J. Clin. 71, 209\u2013249 (2021). https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"Cancer J. Clin."},{"key":"3526_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1590\/2359-3997000000245","volume":"61","author":"A Schmidt","year":"2017","unstructured":"A. Schmidt, L. Iglesias, M. Klain, F. Pitoia, M.J. Schlumberger, Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation. Arch. Endocrinol. Metab. 61, 81\u201389 (2017). https:\/\/doi.org\/10.1590\/2359-3997000000245","journal-title":"Arch. Endocrinol. Metab."},{"key":"3526_CR30","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1177\/030089169007600513","volume":"76","author":"J-P Droz","year":"1990","unstructured":"J.-P. Droz, M. Schlumberger, P. Rougier, M. Ghosn, P. Gardet, C. Parmentier, Chemotherapy in Metastatic Nonanaplastic Thyroid Cancer: Experience at the Institut Gustave-Roussy. Tumor. J. 76, 480\u2013483 (1990). https:\/\/doi.org\/10.1177\/030089169007600513","journal-title":"Tumor. J."},{"key":"3526_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26, 1\u2013133 (2016). https:\/\/doi.org\/10.1089\/thy.2015.0020","journal-title":"Thyroid"},{"key":"3526_CR32","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"M. Schlumberger, M. Tahara, L.J. Wirth, B. Robinson, M.S. Brose, R. Elisei, M.A. Habra, K. Newbold, M.H. Shah, A.O. Hoff, A.G. Gianoukakis, N. Kiyota, M.H. Taylor, S.-B. Kim, M.K. Krzyzanowska, C.E. Dutcus, B. De Las Heras, J. Zhu, S.I. Sherman, Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer. N. Engl. J. Med. 372, 621\u2013630 (2015). https:\/\/doi.org\/10.1056\/NEJMoa1406470","journal-title":"N. Engl. J. Med."},{"key":"3526_CR33","doi-asserted-by":"publisher","first-page":"S1297","DOI":"10.1016\/j.annonc.2022.07.1733","volume":"33","author":"MS Brose","year":"2022","unstructured":"M.S. Brose, J.A. Krajewska, F. Vaisman, A.O. Hoff, E. Hitre, J. Oliver, D.S. Williamson, N. Berry, J. Capdevila Castillon, 1653P Cabozantinib (C) vs placebo (P) in patients (pts) with radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) who progressed after prior VEGFR-targeted therapy: Outcomes by duration of prior lenvatinib (L) treatment. Ann. Oncol. 33, S1297\u2013S1298 (2022). https:\/\/doi.org\/10.1016\/j.annonc.2022.07.1733","journal-title":"Ann. Oncol."},{"key":"3526_CR34","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1089\/thy.2014.0125","volume":"24","author":"ME Cabanillas","year":"2014","unstructured":"M.E. Cabanillas, M.S. Brose, J. Holland, K.C. Ferguson, S.I. Sherman, A Phase I Study of Cabozantinib (XL184) in Patients with Differentiated Thyroid Cancer. Thyroid 24, 1508\u20131514 (2014). https:\/\/doi.org\/10.1089\/thy.2014.0125","journal-title":"Thyroid"},{"key":"3526_CR35","doi-asserted-by":"publisher","first-page":"A31","DOI":"10.1089\/thy.2015.29004.abstracts","volume":"25","author":"MH Shah","year":"2015","unstructured":"M.H. Shah, J. De souza, L. Wirth, M.E. Menefee, S. Liu, S. Geyer, J. Wright, M. Villalona, M. Cabanillas, Cabozantinib in patients with radioiodine-refractory differentiated thyroid cancer who progressed on prior VEGFR-targeted therapy: Results of NCI-and itog-sponsored multicenter phase II clinical trial. Thyroid 25, A31\u2013A32 (2015). https:\/\/doi.org\/10.1089\/thy.2015.29004.abstracts","journal-title":"Thyroid"},{"key":"3526_CR36","doi-asserted-by":"crossref","unstructured":"M.E. Cabanillas, M.S. Brose, D.A. Ramies, Y. Lee, D. Miles, S.I. Sherman, Antitumor activity of cabozantinib (XL184) in a cohort of patients (pts) with differentiated thyroid cancer (DTC), J. Clin. Oncol. 30 (2012). https:\/\/www.embase.com\/search\/results?subaction=viewrecord&id=L71004222&from=export","DOI":"10.1200\/jco.2012.30.15_suppl.5547"},{"key":"3526_CR37","doi-asserted-by":"crossref","unstructured":"B. Konda, M.V. Knopp, P.R. Martin, S. Geyer, M.E. Cabanillas, J.A. De Souza, L.J. Wirth, M.E. Menefee, S.V. Liu, M.H. Shah, Effect of cabozantinib on bone turnover markers (BTM) and bone metastases (BM) in radioiodine refractory (RAIR)-differentiated thyroid cancer (DTC), J. Clin. Oncol. 35 (2017). https:\/\/www.embase.com\/search\/results?subaction=viewrecord&id=L617627373&from=export","DOI":"10.1200\/JCO.2017.35.15_suppl.e17580"},{"key":"3526_CR38","doi-asserted-by":"publisher","first-page":"A98","DOI":"10.1089\/thy.2022.29140.lb.abstracts","volume":"32","author":"B Konda","year":"2022","unstructured":"B. Konda, E. Sherman, E. Massarelli, B. Xia, J. Muzaffar, J. Morris, M. Ryder, A. Ho, M. Agulnik, L. Wei, R. Jacob, J. Wright, H. Streicher, W. Carson, M. Shah, Cabozantinib in combination with nivolumab and ipilimumab in patients with radioiodine (rai)-refractory differentiated thyroid cancer (dtc) whose cancer progressed after one prior vascular endothelial growthfactor receptor (vegfr)-targeted therapy: interim results of a multicenter phase 2 national cancer institute (nci)-international thyroid oncology group (itog) trial (nci#10240). Thyroid 32, A98 (2022). https:\/\/doi.org\/10.1089\/thy.2022.29140.lb.abstracts","journal-title":"Thyroid"},{"key":"3526_CR39","doi-asserted-by":"publisher","first-page":"A3","DOI":"10.1089\/thy.2022.29138.abstracts","volume":"32","author":"M Taylor","year":"2022","unstructured":"M. Taylor, G. Daniels, K. Thein, Y. Loriot, S. Khan, J. Goldschmidt, L. Lebellec, J. Sarantopoulos, A. Vozy, Z. Castel-Ajgal, S. Andrianova, R. Sudhagoni, R. Levytskyy, R. Dadu, Cabozantinib in combination with atezolizumab as a first-line therapy in patients with radioiodine-refractory (rair) differentiated thyroid cancer (dtc): results from cohort 18 of the phase 1b cosmic-21 study. Thyroid 32, A3 (2022). https:\/\/doi.org\/10.1089\/thy.2022.29138.abstracts","journal-title":"Thyroid"},{"key":"3526_CR40","doi-asserted-by":"publisher","unstructured":"M.S. Brose, S. Shenoy, N. Bhat, A.K. Harlacker, R.K. Yurtal, Z.A. Posey, D.M. Torrente, C. Grande, C.M. Squillante, A. Troxel, M. Yarchoan, A phase II trial of cabozantinib (CABO) for the treatment of radioiodine (RAI)-refractory differentiated thyroid carcinoma (DTC) in the first-line setting, J. Clin. Oncol. 36 (2018). https:\/\/doi.org\/10.1200\/JCO.2018.36.15-suppl.6088","DOI":"10.1200\/JCO.2018.36.15-suppl.6088"},{"key":"3526_CR41","doi-asserted-by":"publisher","first-page":"8425","DOI":"10.21037\/apm-20-2483","volume":"10","author":"H Xin","year":"2021","unstructured":"H. Xin, R. Wei, Q. Ma, N. Wang, A. Li, W. Li, Merkel cell carcinoma after liver transplantation: a case report and review of the literature. Ann. Palliat. Med. 10, 8425\u20138430 (2021). https:\/\/doi.org\/10.21037\/apm-20-2483","journal-title":"Ann. Palliat. Med."},{"key":"3526_CR42","doi-asserted-by":"publisher","first-page":"17077","DOI":"10.1038\/nrdp.2017.77","volume":"3","author":"JC Becker","year":"2017","unstructured":"J.C. Becker, A. Stang, J.A. DeCaprio, L. Cerroni, C. Lebb\u00e9, M. Veness, P. Nghiem, Merkel cell carcinoma. Nat. Rev. Dis. Prim. 3, 17077 (2017). https:\/\/doi.org\/10.1038\/nrdp.2017.77","journal-title":"Nat. Rev. Dis. Prim."},{"key":"3526_CR43","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.hoc.2018.08.002","volume":"33","author":"Y Xue","year":"2019","unstructured":"Y. Xue, M. Thakuria, Merkel Cell Carcinoma Review. Hematol. Oncol. Clin. North Am. 33, 39\u201352 (2019). https:\/\/doi.org\/10.1016\/j.hoc.2018.08.002","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"3526_CR44","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1002\/cam4.815","volume":"5","author":"JG Iyer","year":"2016","unstructured":"J.G. Iyer, A. Blom, R. Doumani, C. Lewis, E.S. Tarabadkar, A. Anderson, C. Ma, A. Bestick, U. Parvathaneni, S. Bhatia, P. Nghiem, Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med. 5, 2294\u20132301 (2016). https:\/\/doi.org\/10.1002\/cam4.815","journal-title":"Cancer Med."},{"key":"3526_CR45","doi-asserted-by":"publisher","first-page":"djw042","DOI":"10.1093\/jnci\/djw042","volume":"108","author":"S Bhatia","year":"2016","unstructured":"S. Bhatia, B.E. Storer, J.G. Iyer, A. Moshiri, U. Parvathaneni, D. Byrd, A.J. Sober, V.K. Sondak, J.E. Gershenwald, P. Nghiem, Adjuvant Radiation Therapy and Chemotherapy in Merkel Cell Carcinoma: Survival Analyses of 6908 Cases From the National Cancer Data Base. J. Natl. Cancer Inst. 108, djw042 (2016). https:\/\/doi.org\/10.1093\/jnci\/djw042","journal-title":"J. Natl. Cancer Inst."},{"key":"3526_CR46","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1001\/archderm.139.12.1587","volume":"139","author":"L Mortier","year":"2003","unstructured":"L. Mortier, Radiotherapy Alone for Primary Merkel Cell Carcinoma. Arch. Dermatol. 139, 1587 (2003). https:\/\/doi.org\/10.1001\/archderm.139.12.1587","journal-title":"Arch. Dermatol."},{"key":"3526_CR47","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1200\/JCO.18.01896","volume":"37","author":"P Nghiem","year":"2019","unstructured":"P. Nghiem, S. Bhatia, E.J. Lipson, W.H. Sharfman, R.R. Kudchadkar, A.S. Brohl, P.A. Friedlander, A. Daud, H.M. Kluger, S.A. Reddy, B.C. Boulmay, A.I. Riker, M.A. Burgess, B.A. Hanks, T. Olencki, K. Margolin, L.M. Lundgren, A. Soni, N. Ramchurren, C. Church, S.Y. Park, M.M. Shinohara, B. Salim, J.M. Taube, S.R. Bird, N. Ibrahim, S.P. Fling, B. Homet Moreno, E. Sharon, M.A. Cheever, S.L. Topalian, Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy. J. Clin. Oncol. 37, 693\u2013702 (2019). https:\/\/doi.org\/10.1200\/JCO.18.01896","journal-title":"J. Clin. Oncol."},{"key":"3526_CR48","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2000.18.12.2493","volume":"18","author":"PTH Tai","year":"2000","unstructured":"P.T.H. Tai, E. Yu, E. Winquist, A. Hammond, L. Stitt, J. Tonita, J. Gilchrist, Chemotherapy in Neuroendocrine\/Merkel Cell Carcinoma of the Skin: Case Series and Review of 204 Cases. J. Clin. Oncol. 18, 2493\u20132499 (2000). https:\/\/doi.org\/10.1200\/JCO.2000.18.12.2493","journal-title":"J. Clin. Oncol."},{"key":"3526_CR49","doi-asserted-by":"crossref","unstructured":"H.L. Kaufman, Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after \u22651 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial, 6(1), 7 (2018).","DOI":"10.1186\/s40425-017-0310-x"},{"key":"3526_CR50","doi-asserted-by":"publisher","unstructured":"H. Zhang, Apatinib for molecular targeted therapy in tumor, Drug Des. Devel. Ther. (2015) 6075. https:\/\/doi.org\/10.2147\/DDDT.S97235","DOI":"10.2147\/DDDT.S97235"},{"issue":"7","key":"3526_CR51","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/modpathol.2008.63","volume":"21","author":"M Brunner","year":"2008","unstructured":"M. Brunner, D. Thurnher, J. Pammer, S. Geleff, G. Heiduschka, C.M. Reinisch, P. Petzelbauer, B.M. Erovic, Expression of VEGF-A\/C, VEGF-R2, PDGF-a\/b, c-kit, EGFR, Her-2\/Neu, Mcl-1 and Bmi-1 in Merkel cell carcinoma. Mod. Pathol. 21(7), 876\u201384 (2008)","journal-title":"Mod. Pathol."},{"key":"3526_CR52","doi-asserted-by":"publisher","first-page":"505","DOI":"10.12659\/AJCR.908649","volume":"19","author":"ES Tarabadkar","year":"2018","unstructured":"E.S. Tarabadkar, H. Thomas, A. Blom, U. Parvathaneni, T. Olencki, P. Nghiem, S. Bhatia, Clinical Benefit from Tyrosine Kinase Inhibitors in Metastatic Merkel Cell Carcinoma: A Case Series of 5 Patients. Am. J. Case Rep. 19, 505\u2013511 (2018). https:\/\/doi.org\/10.12659\/AJCR.908649","journal-title":"Am. J. Case Rep."},{"key":"3526_CR53","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1634\/theoncologist.2017-0552","volume":"23","author":"G Rabinowits","year":"2018","unstructured":"G. Rabinowits, C. Lezcano, P.J. Catalano, P. McHugh, H. Becker, M.M. Reilly, J. Huang, A. Tyagi, M. Thakuria, S.C. Bresler, L.M. Sholl, G.I. Shapiro, R. Haddad, J.A. DeCaprio, Cabozantinib in Patients with Advanced Merkel Cell Carcinoma. Oncologist 23, 814\u2013821 (2018). https:\/\/doi.org\/10.1634\/theoncologist.2017-0552","journal-title":"Oncologist"},{"key":"3526_CR54","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/SLA.0000000000002195","volume":"268","author":"A Roman-Gonzalez","year":"2018","unstructured":"A. Roman-Gonzalez, S. Zhou, M. Ayala-Ramirez, C. Shen, S.G. Waguespack, M.A. Habra, J.A. Karam, N. Perrier, C.G. Wood, C. Jimenez, Impact of Surgical Resection of the Primary Tumor on Overall Survival in Patients With Metastatic Pheochromocytoma or Sympathetic Paraganglioma. Ann. Surg. 268, 172\u2013178 (2018). https:\/\/doi.org\/10.1097\/SLA.0000000000002195","journal-title":"Ann. Surg."},{"key":"3526_CR55","doi-asserted-by":"publisher","first-page":"R291","DOI":"10.1530\/ERC-13-0223","volume":"20","author":"C Capatina","year":"2013","unstructured":"C. Capatina, G. Ntali, N. Karavitaki, A.B. Grossman, The management of head-and-neck paragangliomas. Endocr. Relat. Cancer 20, R291\u2013R305 (2013). https:\/\/doi.org\/10.1530\/ERC-13-0223","journal-title":"Endocr. Relat. Cancer"},{"key":"3526_CR56","doi-asserted-by":"publisher","first-page":"623","DOI":"10.2967\/jnumed.118.217463","volume":"60","author":"DA Pryma","year":"2019","unstructured":"D.A. Pryma, B.B. Chin, R.B. Noto, J.S. Dillon, S. Perkins, L. Solnes, L. Kostakoglu, A.N. Serafini, M.H. Pampaloni, J. Jensen, T. Armor, T. Lin, T. White, N. Stambler, S. Apfel, V.A. DiPippo, S. Mahmood, V. Wong, C. Jimenez, Efficacy and Safety of High-Specific-Activity 131 I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma. J. Nucl. Med. 60, 623\u2013630 (2019). https:\/\/doi.org\/10.2967\/jnumed.118.217463","journal-title":"J. Nucl. Med."},{"key":"3526_CR57","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/cen.12542","volume":"81","author":"ND Niemeijer","year":"2014","unstructured":"N.D. Niemeijer, G. Alblas, L.T. van Hulsteijn, O.M. Dekkers, E.P.M. Corssmit, Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta-analysis. Clin. Endocrinol. (Oxf.). 81, 642\u2013651 (2014). https:\/\/doi.org\/10.1111\/cen.12542","journal-title":"Clin. Endocrinol. (Oxf.)."},{"key":"3526_CR58","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1111\/cen.12341","volume":"80","author":"LT van Hulsteijn","year":"2014","unstructured":"L.T. van Hulsteijn, N.D. Niemeijer, O.M. Dekkers, E.P.M. Corssmit, 131 I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis. Clin. Endocrinol. (Oxf.). 80, 487\u2013501 (2014). https:\/\/doi.org\/10.1111\/cen.12341","journal-title":"Clin. Endocrinol. (Oxf.)."},{"key":"3526_CR59","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3389\/fendo.2018.00277","volume":"9","author":"C Jimenez","year":"2018","unstructured":"C. Jimenez, Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer. Front. Endocrinol. 9, 277 (2018). https:\/\/doi.org\/10.3389\/fendo.2018.00277","journal-title":"Front. Endocrinol."},{"key":"3526_CR60","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","volume":"120","author":"GM O\u2019Kane","year":"2019","unstructured":"G.M. O\u2019Kane, S. Ezzat, A.M. Joshua, I. Bourdeau, R. Leibowitz-Amit, H.J. Olney, M. Krzyzanowska, D. Reuther, S. Chin, L. Wang, K. Brooks, A.R. Hansen, S.L. Asa, J.J. Knox, A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. Br. J. Cancer 120, 1113\u20131119 (2019). https:\/\/doi.org\/10.1038\/s41416-019-0474-x","journal-title":"Br. J. Cancer"},{"key":"3526_CR61","doi-asserted-by":"publisher","first-page":"594264","DOI":"10.3389\/fendo.2020.594264","volume":"11","author":"MP Economides","year":"2020","unstructured":"M.P. Economides, A.Y. Shah, C. Jimenez, M.A. Habra, M. Desai, M.T. Campbell, A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature. Front. Endocrinol. 11, 594264 (2020). https:\/\/doi.org\/10.3389\/fendo.2020.594264","journal-title":"Front. Endocrinol."},{"key":"3526_CR62","doi-asserted-by":"publisher","first-page":"3672","DOI":"10.1200\/JCO.20.01652","volume":"38","author":"AB Apolo","year":"2020","unstructured":"A.B. Apolo, R. Nadal, D.M. Girardi, S.A. Niglio, L. Ley, L.M. Cordes, S.M. Steinberg, O. Sierra Ortiz, J. Cadena, C. Diaz, M. Mallek, N.N. Davarpanah, R. Costello, J.B. Trepel, M.-J. Lee, M.J. Merino, M.H. Bagheri, P. Monk, W.D. Figg, J.L. Gulley, P.K. Agarwal, V. Valera, H.J. Chalfin, J. Jones, H. Streicher, J.J. Wright, Y.M. Ning, H.L. Parnes, W.L. Dahut, D.P. Bottaro, P.N. Lara, B. Saraiya, S.K. Pal, M.N. Stein, A. Mortazavi, Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors. J. Clin. Oncol. 38, 3672\u20133684 (2020). https:\/\/doi.org\/10.1200\/JCO.20.01652","journal-title":"J. Clin. Oncol."},{"key":"3526_CR63","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/MED.0000000000000330","volume":"24","author":"A Roman-Gonzalez","year":"2017","unstructured":"A. Roman-Gonzalez, C. Jimenez, Malignant pheochromocytoma\u2013paraganglioma: pathogenesis, TNM staging, and current clinical trials. Curr. Opin. Endocrinol. Diabetes Obes. 24, 174\u2013183 (2017). https:\/\/doi.org\/10.1097\/MED.0000000000000330","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"3526_CR64","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","volume":"179","author":"M Fassnacht","year":"2018","unstructured":"M. Fassnacht, O.M. Dekkers, T. Else, E. Baudin, A. Berruti, R.R. de Krijger, H.R. Haak, R. Mihai, G. Assie, M. Terzolo, European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur. J. Endocrinol. 179, G1\u2013G46 (2018). https:\/\/doi.org\/10.1530\/EJE-18-0608","journal-title":"Eur. J. Endocrinol."},{"key":"3526_CR65","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1210\/er.2013-1029","volume":"35","author":"T Else","year":"2014","unstructured":"T. Else, A.C. Kim, A. Sabolch, V.M. Raymond, A. Kandathil, E.M. Caoili, S. Jolly, B.S. Miller, T.J. Giordano, G.D. Hammer, Adrenocortical Carcinoma. Endocr. Rev. 35, 282\u2013326 (2014). https:\/\/doi.org\/10.1210\/er.2013-1029","journal-title":"Endocr. Rev."},{"key":"3526_CR66","unstructured":"T. Massimo, A. Alberto, F. Martin, D. Fulvia, T. Libuse, C.P. Antonio, R. Ruth, B. Lisa, S. Paola, G. Erika, R. Giuseppe, B. Enrico, P. Mauro, S. Wolfgang, H. Stefanie, K. Ann-Cathrin, A. Emanuela, A. Bruno, L. Paola, L. Gaetano, M. Massimo, B. Paolo, M. Franco, A. Bruno, D. Luigi, B. Alfredo, Adjuvant Mitotane Treatment for Adrenocortical Carcinoma, N. Engl. J. Med. 356:2372\u20132380 (2007)"},{"key":"3526_CR67","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","volume":"366","author":"M Fassnacht","year":"2012","unstructured":"M. Fassnacht, M. Terzolo, B. Allolio, E. Baudin, H. Haak, A. Berruti, S. Welin, C. Schade-Brittinger, A. Lacroix, B. Jarzab, H. Sorbye, D.J. Torpy, V. Stepan, D.E. Schteingart, W. Arlt, M. Kroiss, S. Leboulleux, P. Sperone, A. Sundin, I. Hermsen, S. Hahner, H.S. Willenberg, A. Tabarin, M. Quinkler, C. de la Fouchardi\u00e8re, M. Schlumberger, F. Mantero, D. Weismann, F. Beuschlein, H. Gelderblom, H. Wilmink, M. Sender, M. Edgerly, W. Kenn, T. Fojo, H.-H. M\u00fcller, B. Skogseid, Combination Chemotherapy in Advanced Adrenocortical Carcinoma. N. Engl. J. Med. 366, 2189\u20132197 (2012). https:\/\/doi.org\/10.1056\/NEJMoa1200966","journal-title":"N. Engl. J. Med."},{"key":"3526_CR68","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1530\/EJE-11-0918","volume":"166","author":"A Berruti","year":"2012","unstructured":"A. Berruti, P. Sperone, A. Ferrero, A. Germano, A. Ardito, A.M. Priola, S. De Francia, M. Volante, F. Daffara, D. Generali, S. Leboulleux, P. Perotti, E. Baudin, M. Papotti, M. Terzolo, Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma. Eur. J. Endocrinol. 166, 451\u2013458 (2012). https:\/\/doi.org\/10.1530\/EJE-11-0918","journal-title":"Eur. J. Endocrinol."},{"key":"3526_CR69","doi-asserted-by":"publisher","first-page":"4131","DOI":"10.1158\/0008-5472.CAN-14-3707","volume":"75","author":"LM Phan","year":"2015","unstructured":"L.M. Phan, E. Fuentes-Mattei, W. Wu, G. Velazquez-Torres, K. Sircar, C.G. Wood, T. Hai, C. Jimenez, G.J. Cote, L. Ozsari, M.-C. Hofmann, S. Zheng, R. Verhaak, L. Pagliaro, M.A. Cortez, M.-H. Lee, S.-C.J. Yeung, M.A. Habra, Hepatocyte Growth Factor\/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. Cancer Res. 75, 4131\u20134142 (2015). https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-3707","journal-title":"Cancer Res."},{"key":"3526_CR70","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1210\/clinem\/dgz318","volume":"105","author":"M Kroiss","year":"2020","unstructured":"M. Kroiss, F. Megerle, M. Kurlbaum, S. Zimmermann, J. Wendler, C. Jimenez, C. Lapa, M. Quinkler, O. Scherf-Clavel, M.A. Habra, M. Fassnacht, Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib. J. Clin. Endocrinol. Metab. 105, 1461\u20131468 (2020). https:\/\/doi.org\/10.1210\/clinem\/dgz318","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3526_CR71","doi-asserted-by":"publisher","first-page":"bvaa069","DOI":"10.1210\/jendso\/bvaa069","volume":"4","author":"KC Miller","year":"2020","unstructured":"K.C. Miller, A.V. Chintakuntlawar, C. Hilger, I. Bancos, J.C. Morris, M. Ryder, C.Y. Smith, S.M. Jenkins, K.C. Bible, Salvage Therapy With Multikinase Inhibitors and Immunotherapy in Advanced Adrenal Cortical Carcinoma. J. Endocr. Soc. 4, bvaa069 (2020). https:\/\/doi.org\/10.1210\/jendso\/bvaa069","journal-title":"J. Endocr. Soc."},{"key":"3526_CR72","doi-asserted-by":"publisher","first-page":"R453","DOI":"10.1530\/ERC-17-0531","volume":"25","author":"F Grillo","year":"2018","unstructured":"F. Grillo, T. Florio, F. Ferra\u00f9, E. Kara, G. Fanciulli, A. Faggiano, A. Colao, Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms. Endocr. Relat. Cancer 25, R453\u2013R466 (2018). https:\/\/doi.org\/10.1530\/ERC-17-0531","journal-title":"Endocr. Relat. Cancer"},{"key":"3526_CR73","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000443172","volume":"103","author":"R Garcia-Carbonero","year":"2016","unstructured":"R. Garcia-Carbonero, H. Sorbye, E. Baudin, E. Raymond, B. Wiedenmann, B. Niederle, E. Sedlackova, C. Toumpanakis, M. Anlauf, J.B. Cwikla, M. Caplin, D. O\u201dToole, A. Perren; all other Vienna Consensus Conference participants, ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology 103, 186\u2013194 (2016). https:\/\/doi.org\/10.1159\/000443172","journal-title":"Neuroendocrinology"},{"key":"3526_CR74","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000443167","volume":"103","author":"M Pavel","year":"2016","unstructured":"M. Pavel, D. O\u2019Toole, F. Costa, J. Capdevila, D. Gross, R. Kianmanesh, E. Krenning, U. Knigge, R. Salazar, U.-F. Pape, K. \u00d6berg; all other Vienna Consensus Conference participants, ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology 103, 172\u2013185 (2016). https:\/\/doi.org\/10.1159\/000443167","journal-title":"Neuroendocrinology"},{"key":"3526_CR75","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","volume":"26","author":"JC Yao","year":"2008","unstructured":"J.C. Yao, M. Hassan, A. Phan, C. Dagohoy, C. Leary, J.E. Mares, E.K. Abdalla, J.B. Fleming, J.-N. Vauthey, A. Rashid, D.B. Evans, One Hundred Years After \u201cCarcinoid\u201d: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. J. Clin. Oncol. 26, 3063\u20133072 (2008). https:\/\/doi.org\/10.1200\/JCO.2007.15.4377","journal-title":"J. Clin. Oncol."},{"key":"3526_CR76","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1056\/NEJMoa1003825","volume":"364","author":"E Raymond","year":"2011","unstructured":"E. Raymond, L. Dahan, J.-L. Raoul, Y.-J. Bang, I. Borbath, C. Lombard-Bohas, J. Valle, P. Metrakos, D. Smith, A. Vinik, J.-S. Chen, D. H\u00f6rsch, P. Hammel, B. Wiedenmann, E. Van Cutsem, S. Patyna, D.R. Lu, C. Blanckmeister, R. Chao, P. Ruszniewski, Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. N. Engl. J. Med. 364, 501\u2013513 (2011). https:\/\/doi.org\/10.1056\/NEJMoa1003825","journal-title":"N. Engl. J. Med."},{"key":"3526_CR77","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1159\/000439431","volume":"103","author":"C Reuther","year":"2016","unstructured":"C. Reuther, V. Heinzle, M. Spampatti, G. Vlotides, E. De Toni, G. Sp\u00f6ttl, J. Maurer, S. N\u00f6lting, B. G\u00f6ke, C.J. Auernhammer, Cabozantinib and Tivantinib, but Not INC280, Induce Antiproliferative and Antimigratory Effects in Human Neuroendocrine Tumor Cells in vitro: Evidence for \u201cOff-Target\u201d Effects Not Mediated by c-Met Inhibition. Neuroendocrinology 103, 383\u2013401 (2016). https:\/\/doi.org\/10.1159\/000439431","journal-title":"Neuroendocrinology"},{"key":"3526_CR78","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1158\/2159-8290.CD-11-0240","volume":"2","author":"B Sennino","year":"2012","unstructured":"B. Sennino, T. Ishiguro-Oonuma, Y. Wei, R.M. Naylor, C.W. Williamson, V. Bhagwandin, S.P. Tabruyn, W.-K. You, H.A. Chapman, J.G. Christensen, D.T. Aftab, D.M. McDonald, Suppression of Tumor Invasion and Metastasis by Concurrent Inhibition of c-Met and VEGF Signaling in Pancreatic Neuroendocrine Tumors. Cancer Discov. 2, 270\u2013287 (2012). https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0240","journal-title":"Cancer Discov."},{"key":"3526_CR79","doi-asserted-by":"crossref","unstructured":"J.A. Chan, J.E. Faris, J.E. Murphy, L.S. Blaszkowsky, E.L. Kwak, N.J. McCleary, C.S. Fuchs, J.A. Meyerhardt, K. Ng, A.X. Zhu, T.A. Abrams, B.M. Wolpin, S. Zhang, A. Reardon, B. Fitzpatrick, M.H. Kulke, D.P. Ryan, Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET), J. Clin. Oncol. 35 (2017). https:\/\/www.embase.com\/search\/results?subaction=viewrecord&id=L618086990&from=export","DOI":"10.1200\/JCO.2017.35.4_suppl.228"},{"key":"3526_CR80","doi-asserted-by":"publisher","first-page":"175883592110180","DOI":"10.1177\/17588359211018047","volume":"13","author":"S Das","year":"2021","unstructured":"S. Das, A. Dasari, Novel therapeutics for patients with well-differentiated gastroenteropancreatic neuroendocrine tumors. Ther. Adv. Med. Oncol. 13, 175883592110180 (2021). https:\/\/doi.org\/10.1177\/17588359211018047","journal-title":"Ther. Adv. Med. Oncol."},{"key":"3526_CR81","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s12094-019-02167-y","volume":"22","author":"J Feliu","year":"2020","unstructured":"J. Feliu, V. Heredia-Soto, R. Giron\u00e9s, B. Jim\u00e9nez-Munarriz, J. Salda\u00f1a, C. Guill\u00e9n-Ponce, M.J. Molina-Garrido, Management of the toxicity of chemotherapy and targeted therapies in elderly cancer patients. Clin. Transl. Oncol. 22, 457\u2013467 (2020). https:\/\/doi.org\/10.1007\/s12094-019-02167-y","journal-title":"Clin. Transl. Oncol."},{"key":"3526_CR82","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1634\/theoncologist.2012-0351","volume":"18","author":"SG Mohile","year":"2013","unstructured":"S.G. Mohile, M. Hardt, W. Tew, C. Owusu, H. Klepin, C. Gross, A. Gajra, S.M. Lichtman, T. Feng, K. Togawa, R. Ramani, V. Katheria, K. Hansen, A. Hurria; Cancer and Aging Research Group., Toxicity of Bevacizumab in Combination with Chemotherapy in Older Patients. Oncologist 18, 408\u2013414 (2013). https:\/\/doi.org\/10.1634\/theoncologist.2012-0351","journal-title":"Oncologist"},{"key":"3526_CR83","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.1200\/JCO.2015.65.5597","volume":"34","author":"M Smith","year":"2016","unstructured":"M. Smith, J. De Bono, C. Sternberg, S. Le Moulec, S. Oudard, U. De Giorgi, M. Krainer, A. Bergman, W. Hoelzer, R. De Wit, M. B\u00f6gemann, F. Saad, G. Cruciani, A. Thiery-Vuillemin, S. Feyerabend, K. Miller, N. Hou\u00e9d\u00e9, S. Hussain, E. Lam, J. Polikoff, A. Stenzl, P. Mainwaring, D. Ramies, C. Hessel, A. Weitzman, K. Fizazi, Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. J. Clin. Oncol. 34, 3005\u20133013 (2016). https:\/\/doi.org\/10.1200\/JCO.2015.65.5597","journal-title":"J. Clin. Oncol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03526-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-023-03526-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03526-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T08:34:36Z","timestamp":1705998876000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-023-03526-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,18]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["3526"],"URL":"https:\/\/doi.org\/10.1007\/s12020-023-03526-0","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,18]]},"assertion":[{"value":"9 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent was obtained from the patient and his parents for publication of this case report and any accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}